Related Experiment Video

Updated: Mar 10, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.1K

First Anti-PD-L1 Drug Approved for NSCLC

    Cancer Discovery
    |December 7, 2016
    PubMed

    Abstract:

    Based on the results of two large international randomized trials, the FDA approved the anti-PD-L1 agent atezolizumab in October. It is the first PD-L1 inhibitor approved for use in patients with metastatic non-small cell lung cancer that has advanced in spite of treatment with platinum-based chemotherapy.

    More Related Videos

    Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
    07:04

    Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

    Published on: May 2, 2025

    1.3K
    Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
    10:29

    Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

    Published on: August 14, 2019

    11.2K

    Related Experiment Videos

    Last Updated: Mar 10, 2026

    Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
    07:43

    Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

    Published on: September 25, 2018

    11.1K
    Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
    07:04

    Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

    Published on: May 2, 2025

    1.3K
    Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
    10:29

    Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

    Published on: August 14, 2019

    11.2K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    9.0K
    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.0K

    Articles linked to this work by shared authors, journal, and citation graph.

    Transmissible Cancer Discovered in Catfish.

    Cancer discovery·2026

    Follicular Lymphoma Transformation is Characterized by Cytokine-associated Remodeling of Stromal and Macrophage Compartments.

    Cancer discovery·2026

    Genomics of Subsequent Neoplasms in Childhood Cancer Survivors.

    Cancer discovery·2026

    A Counterintuitive Approach to Cancer Therapy.

    Cancer discovery·2026

    Rare Fusions, Real Targets: Ultraprecision Oncology in Lung Cancer.

    Cancer discovery·2026

    Lung Tumors Hack Nervous System to Drive Cachexia.

    Cancer discovery·2026

    Synergistic cell-cycle repression by HDAC/EZH2 co-targeting in H3K27-altered diffuse midline glioma.

    Molecular therapy. Oncology·2026

    In-depth characterization of stem cell potency and genotoxicity for clinical-scale ex vivo CRISPR-Cas9 gene editing.

    Molecular therapy. Advances·2026

    m6A-dependent regulation of DGUOK-AS1 by RBM15 and HNRNPH1 in lung adenocarcinoma.

    iScience·2026

    Metabolic reprogramming in pancreatic cancer: interplay of glucose, lipid, and amino acid metabolism in tumor progression.

    Cytotechnology·2026

    Baicalein targets the Nrf2/Keap1 interaction and related stress pathways to mitigate drug-induced toxicity and reverse resistance in breast cancer: A review.

    International journal of biological macromolecules·2026

    Exosomes as next-generation drug carriers: Transforming cancer therapy.

    Journal of controlled release : official journal of the Controlled Release Society·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us